GenLives
- Company typePrivate
- Founded2016
- HeadquartersMontevideo, Uruguay
- Headcount1–10
- GTM typeB2B
- OfferingServices
GenLives firmographics
Firmographics- Name
- GenLives
- Legal name
- GenLives
- Website
- https://genlives.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
GenLives industry classification
Industry- Product category
- Clinical Genomic Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic & Prenatal Testing Laboratories (HLAFAMAH)
- akta.pro secondary industries
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where GenLives is headquartered
LocationHeadquarters
- HQ city
- Montevideo
- HQ country
- Uruguay
- HQ region
- Latin America
Offices2 records
Markets served
GenLives business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Genomic Testing Services: Clinical genomic testing services including whole exome sequencing, whole genome sequencing, and targeted gene panels for hereditary cancers, cardiomyopathies, neurology, and pre-reproduction. Revenue generated through individual test orders placed by physicians on the platform.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
GenLives product offering
Product offeringCore offering
GenLives provides clinical genomic testing services in Uruguay using next-generation sequencing (NGS), including whole exome sequencing (~20,000 genes), whole genome sequencing (~3 billion bases), and targeted gene panels for hereditary cancers (BRCA1/2, colon), cardiomyopathies, neurology (Alzheimer, Parkinson), pre-reproduction carrier screening, and histamine intolerance (DAO). Studies are ordered exclusively through a physician-mediated platform and include pre- and post-study genetic counseling delivered by a multidisciplinary team of geneticists, bioinformaticians, and molecular biologists at no additional cost.
Product overview
GenLives is a precision genomic diagnostics company offering a unified portfolio of genomic studies for clinical use. The core products include Complete Exome (sequencing ~20,000 coding genes) and Complete Genome (sequencing ~3 billion DNA bases), supplemented by targeted add-on panels for specific conditions including hereditary cancers (breast cancer BRCA1/BRAC2, colon cancer), genetic cardiology (long/short QT, cardiomyopathies, Brugada), genetic neurology (Alzheimer, Parkinson), histamine intolerance (DAO), and pre-reproduction carrier screening. All studies are supported by a proprietary physician platform for online study requests, real-time tracking, and report access, plus included genetic counseling services provided by a multidisciplinary team of geneticists, bioinformaticians, and molecular biologists.
Differentiator
Problem solved
Functional benefit
Products and services
- Exoma Completo (Complete Exome) Sequencing of all protein-coding genes (~20,000 genes) providing a comprehensive view for differential diagnosis and diseases of unknown cause. Targeted at patients with rare or undiagnosed genetic conditions, ordered through their treating physician.
- Genoma Completo (Complete Genome) Whole genome sequencing of approximately 3 billion bases of human DNA, detecting any variant type in any genome region for the most powerful genomic diagnostic and prevention capability. Ordered through treating physicians for patients requiring comprehensive genomic analysis.
- Pre-Reproducción (Pre-Reproduction Carrier Screening) Study for couples planning to conceive that detects carrier status for recessive genetic diseases to support informed family planning. Ordered by physicians on behalf of couples.
- Cáncer de Mama (Hereditary Breast and Ovarian Cancer Panel) Analysis of BRCA1, BRCA2 and other susceptibility genes for hereditary breast and ovarian cancer. Ordered by physicians for patients with personal or family history suggesting hereditary cancer risk.
- Cáncer de Colon (Hereditary Colon Cancer Panel) Genetic analysis for hereditary colon cancer susceptibility. Ordered by physicians for patients with personal or family history suggesting hereditary colon cancer risk.
- Cardiopatías Genéticas (Genetic Cardiopathies Panel) Panels for hereditary cardiopathies including long/short QT, cardiomyopathies, arrhythmias, and Brugada syndrome. Ordered by cardiologists for patients with suspected inherited cardiovascular conditions.
- Neurología Genética - Alzheimer (Genetic Neurology – Alzheimer) Genetic predisposition study for Alzheimer disease, providing information for prevention and care planning. Ordered by physicians for at-risk patients.
- Neurología Genética - Parkinson (Genetic Neurology – Parkinson) Genetic predisposition study for Parkinson disease, providing information for prevention and care planning. Ordered by physicians for at-risk patients.
- Intolerancia Histamina DAO (Histamine Intolerance DAO Panel) Genetic analysis for histamine intolerance related to DAO (diamine oxidase) enzyme deficiency. Ordered by physicians for symptomatic patients.
- Asesoramiento Genético (Genetic Counseling) Pre- and post-study genetic counseling delivered by geneticists, bioinformaticians, and molecular biologists. Included at no additional cost with every GenLives genomic study to support patients and prescribing physicians in interpreting results.
Quantifiable outcome
- 8+ years average diagnostic delay in Latin America for genetic diseases can be reduced through early genomic testing
- +2 more outcomes
Companies that use GenLives
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
GenLives technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
GenLives partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Institut Pasteur de MontevideocoreMultiple team members hold positions at Institut Pasteur de Montevideo (Dra. Lucía Spangenberg as researcher, Dr. Hugo Naya as Head of Bioinformatics Unit and coordinator of URUGENOMES project, Lic. Daniela Megrián as bioinformatician). The institution provides research infrastructure and expertise supporting GenLives operations.
- UDELAR (Universidad de la República)minorDr. Víctor Raggio serves as Profesor Agregado de Genética Clínica at the Faculty of Medicine, UDELAR. Team members teach at UDELAR institutions, providing academic and research collaboration.
- Universidad ORT UruguayminorTeam members (Dra. Lucía Spangenberg and Lic. Daniela Megrián) serve as bioinformatics lecturers at Universidad ORT Uruguay, providing academic collaboration and talent development.
Scale indicators6 records
Recent moves1 record
Expansion highlights4 records
GenLives competitors and assessment
Company assessmentDirect peers
- Dante Labs: Italy-based whole-genome sequencing provider selling direct-to-consumer and clinical WGS with bioinformatics interpretation. Comparable technology stack (NGS WGS at scale) and variant interpretation pipeline, though distribution model differs.
- Veritas Genetics: Whole-genome sequencing company offering clinical and consumer genomics with integrated genetic counseling. Directly comparable technology portfolio (WGS, carrier screening, hereditary panels) and clinical interpretation emphasis.
- Centogene: Germany-based rare disease diagnostics laboratory providing whole-exome, whole-genome, and targeted panels with integrated genetic interpretation. Directly comparable focus on rare-disease diagnostic odyssey, multi-database annotation, and physician-mediated clinical reporting.
- Mendelics: Brazilian clinical genomics laboratory offering exome, genome, and hereditary cancer panels with physician-mediated ordering. Closest regional peer given geographic adjacency, language overlap, and similar B2B2C clinical model in Latin America.
Emerging players
- MedGenome: India-headquartered genomics diagnostics company providing WES, WGS, and rare-disease panels with physician ordering workflow. Similar emerging-market positioning, multi-omic test menu, and focus on serving underserved populations in South Asia — a useful structural analog.
- Mapmygenome: India-based preventive and clinical genomics company offering whole-genome, hereditary panels, and pharmacogenomics with genetic counseling. Comparable portfolio breadth (WGS + targeted panels + counseling), with physician-mediated and consumer channels.
Broad incumbents
- Natera: US-based genetic testing company offering reproductive, oncology, and hereditary panels with bioinformatics interpretation. Comparable clinical genetic testing capabilities but with broader reimbursement infrastructure and scaled sales coverage.
- Invitae (Labcorp Genetics): Large US-based clinical genetic testing laboratory (now part of Labcorp) offering broad hereditary panels, WES/WGS, and reproductive screening. Represents scaled competition with similar test menu and bioinformatics depth.
- 23andMe: US consumer genomics company offering DTC genetic tests including health predisposition and carrier screening. Represents the consumer/D2C end of the genomic testing continuum; a potential distribution model alternative for GenLives.
- Color Genomics: US preventive genomics company offering hereditary cancer, cardiovascular, and pharmacogenomic panels with integrated counseling. Comparable focus on hereditary cancer (BRCA) and cardiac panels, scaled via employer and provider partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
GenLives social profiles
Digital presenceGenLives compliance and trust
Trust signalCompliance1 record
GenLives financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenLives leadership team
Management profileNumber of profiles
Profiles7 records
GenLives funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenLives M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenLives
What does GenLives do?
GenLives provides clinical genomic testing services in Uruguay using next-generation sequencing (NGS), including whole exome sequencing (~20,000 genes), whole genome sequencing (~3 billion bases), and targeted gene panels for hereditary cancers (BRCA1/2, colon), cardiomyopathies, neurology (Alzheimer, Parkinson), pre-reproduction carrier screening, and histamine intolerance (DAO). Studies are ordered exclusively through a physician-mediated platform and include pre- and post-study genetic counseling delivered by a multidisciplinary team of geneticists, bioinformaticians, and molecular biologists at no additional cost.
Is GenLives a public or private company?
GenLives is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was GenLives founded?
GenLives was founded in 2016. It employs 1 to 10 people.
Where is GenLives based?
GenLives is headquartered in Montevideo, Uruguay, in the Latin America region.
How does GenLives make money?
One revenue line is on record: genomic Testing Services.
Who are GenLives's main competitors?
Direct peers on record are Dante Labs, Veritas Genetics, Centogene and Mendelics. Emerging players are MedGenome and Mapmygenome. Broad incumbents are Natera, Invitae (Labcorp Genetics), 23andMe and Color Genomics.
Does GenLives have an API?
No public API is recorded for GenLives.
What industry is GenLives in?
GenLives's product category is Clinical Genomic Diagnostics. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 6215 and its SIC code is 8071.